Tag: HCV

CATIE’s HepCInfo Update 5.14

New and Noteworthy Health Canada approves a stand-alone ribavirin pill Health Canada has approved a stand-alone ribavirin pill known by the brand name Ibavyr. Traditionally, ribavirin has been available for Hep C treatment in combination with peg-interferon. A stand-alone ribavirin pill is necessary for some treatments with sofosbuvir (Sovaldi) as well as other interferon-free combinations… Read more »

No More Silos: A Good Practices Guide on undertaking an integrated approach to HIV and hepatitis C identifies practices community-based organizations, community health centres, clinics and other health and social services are engaging to do HIV and hepatitis C work concurrently. No More Silos has two goals: to assist organizations considering undertaking an integrated approach… Read more »

Since 2000, the Millennium Development Goals (MDGs) have successfully mobilized global action around a set of important social priorities, ranging from poverty, disease, unmet schooling, gender inequality and environmental degradation. While substantial progress has been made in achieving the MDGs, there is global agreement that the fight to address such social issues must continue beyond 2015. In… Read more »

PAN’s Mental Health, Substance Use, HIV and HCV Research Team has been planning a research project focusing on the role of community-based organizations in implementing and adapting “best practice” models of frontline care – including case management, community development and community capacity building. As part of the planning stages of this project titled: Making it… Read more »

CATIE’s HepCInfo Update 5.10

New and Noteworthy Application to Health Canada submitted for approval of AbbVie anti-hep C drug combination AbbVie has filed a new drug submission to Health Canada for approval of a combination of drugs for adults with genotype 1 hepatitis C virus. The treatment consists of: ombitasvir and ABT-450 boosted with ritonavir as a fixed dose,… Read more »

The mission of the BC HIV/HCV Evaluation Advisory Group is to: (i) ensure the best HIV/HCV programming for people living-with or at-risk of HIV/HCV; (ii) build a culture of evaluation and research; and increase (iii) evaluation capacity in all HIV/HCV service providers and funders in BC. The Advisory Group is composed of program managers and Executive… Read more »

CATIE – HepCinfo Update 5.7

New and Noteworthy World Health Organization releases global guidelines for Hep C treatment The World Health Organization (WHO) has released global guidelines for the screening, care and treatment of people with hepatitis C. The guidelines recommend: Sofosbuvir (Sovaldi) and ribavirin with genotype 1,2,3 or 4 virus, with or without peg-interferon, depending on the genotype, or;… Read more »

CATIE News – Sleep disturbances and hepatitis C virus

Hepatitis C virus (HCV) infects the liver and injures this organ. If HCV is left untreated, over time this virus continues to injure the liver, causing inflammation and the replacement of healthy, functional liver tissue with scar tissue. In chronic HCV infection, the liver gradually becomes dysfunctional, complications occur and the risk of developing liver… Read more »

CATIE’s HepCInfo Update 5.6

New and Noteworthy In this issue of HepCinfo Update, we cover selected results from four clinical trials of Hep C medication combinations presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). These trials are noteworthy for a number of reasons: The cure rates in all of these trials are very high (85-99%)…. Read more »